期刊文献+

恶性胸膜间皮瘤51例临床分析 被引量:2

下载PDF
导出
摘要 目的回顾性分析51例恶性胸膜间皮瘤的临床特点,以提高恶性胸膜间皮瘤的诊治水平。方法分析51例胸膜间皮瘤的临床资料,包括年龄、石棉接触史、临床表现、影像学检查、实验室检查,用Kaplan-Meier模型的Log-rank检验分析年龄、性别、侵犯范围、分期和治疗方式等因素与预后的关系,用Cox模型分析影响预后的独立危险因素。结果仅1例患者有明确石棉接触史;28例患者曾被误诊为结核性胸膜炎;51例均有不规则胸膜增厚。弥漫性增厚者共42例,局限性胸膜增厚有9例,47例可见纵隔胸膜受累。51例恶性胸膜间皮瘤患者的中位生存时间为6.75个月(范围0.22~91.20个月)。在单因素生存分析中,用单因素生存分析,侵犯范围、年龄和分期与预后相关,多因素Cox回归模型分析发现,局限型恶性胸膜间皮瘤预后较好。结论胸膜活检及免疫组化是确诊恶性胸膜间皮瘤的主要方法,侵犯范围是预后的独立影响因素。
出处 《中国医刊》 CAS 2011年第9期71-74,共4页 Chinese Journal of Medicine
  • 相关文献

参考文献18

  • 1Robinson BW, Lake RA. Advances in malignant mesothelioma[ J] N Engl J Meal,2005,353(15): 1591 -1603.
  • 2P. Van Schil. Malignant pleural mesothelioma: Staging system[ J] Lung Cancer, 2005, 49s1:45-48.
  • 3Pass HI, Donington .IS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences [ J ]. J Thorac Cardiovasc Surg, 1998,116 ( 5 ) : 854 - 859.
  • 4Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma[ J ]. Semin Oncol,2002,29 ( 1 ) : 2 - 17.
  • 5Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1 : Diagnosis [ J]. Cancer, 1993,72(2) : 389 - 393.
  • 6Boutin C, Rey F, Gouvernet J, et al. Thoracoseopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2 : Prognosis and staging [ J ]. Cancer, 1993,72 ( 2 ) : 394 - 404.
  • 7Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma[ J]. World J Surg,2001,25 ( 2 ) : 210 - 217.
  • 8Hughes RS. Malignant pleural mesothelioma [ J ]. Am J Med Sci, 2005,329 ( 1 ) : 29 - 44.
  • 9Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma : evaluation with CT, MR imaging, and PET [ J ]. Radiographics, 2004,24( 1 ) : 105 - 119.
  • 10陈应泰,王俊.恶性胸膜间皮瘤及其诊疗进展[J].中华胸心血管外科杂志,2004,20(4):253-255. 被引量:12

二级参考文献30

  • 1张敦华,钮善福,屠春林,陈英男.胸腔镜检术对胸腔积液病因的诊断和治疗价值[J].中华内科杂志,1996,35(6):367-370. 被引量:37
  • 2齐书山,吕可洁,祁昕,吴鹏涛,袁洪志.电视胸腔镜诊断恶性胸腔积液及榄香烯治疗临床效果[J].中国医刊,2006,41(3):42-43. 被引量:5
  • 3Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol,1997,145:211-218.
  • 4Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg, 2001,25:210-217.
  • 5Fraire AE, Cooper S, Greenberg SD, et al. Mesothelioma of childhood. Cancer, 1988,62:838-847.
  • 6Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med, 1965,22:261-269.
  • 7Pass HI, Donington JS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg, 1998,116:854-859.
  • 8Cicala C, Pompetti F, Carbone M. SV40 induces mesothelilmas in hamsters. Am J Pathol, 1993,142:1524-1533.
  • 9Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol, 2002,29:2-17.
  • 10Roberts JR. Surgical treatment of mesothelioma: pleurectomy. Chest,1999,116(6 Suppl):s446-449.

共引文献17

同被引文献20

  • 1Zucali PA, De Vincenzo F, Simonelli M, et al. Future develop- ments in the management of malignant pleural mesothelioma [ J ]. Expert Rev Anticancer Ther, 2009,9(4) :453-467.
  • 2Chen SE, Pace MB. Malignant pleural mesothelioma [ J ]. Am J Health Syst Pharm, 2012,69 (5) :377-385.
  • 3Oken MM, Creech RH, Tormey DC, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group[ J]. Am J Clin Oncol, 1982,5:649-655.
  • 4Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treat- ment of malignant pleural mesothelioma[J]. Curr Treat Options On- col,2008,9 ( 2-3 ) : 158-170.
  • 5Robinson BW, Lake RA. Advances in malignant mesothelioma[ J]. N Engl J Med, 2005,353:1591-1603.
  • 6Campbell NP, Kindler HL. Update on Malignant Pleural Mesothelio- ma[J]. Semin Respir Crit Care Med,2011,32( 1 ) :102-110.
  • 7Robinson BW, Musk AW, Lake RA. Malignant mesothelioma[J]. Lancet, 2005,366:397-408.
  • 8Otsuka H, Terazawa K, Morita N, et al. Is FDG-PET/CT useful for managing malignant pleural mesothelioma [ J ]. J Med Invest, 2009, 56(1-2) :16-20.
  • 9Yildirim H, Metintas M, Entok E, et al. Clinical value of fluorode- oxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related be- nign pleural disease: an observationl pilot study [ J ]. J Thorac On- col, 2009,4(12) :1480-1484.
  • 10Husain AN,Colby TV, Ordonez NG, et al. Guidelines for patholog- ic diagnosis of malignant: a consensus statement from the Interna- tional Mesothelioma Interest Group [ J ]. Arch Pathol Lab Med, 2009,133(8) :1317-1331.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部